UPDATE 3-Ionis, Biogen drug for fatal infant disorder succeeds in key study

UPDATE 3-Ionis, Biogen drug for fatal infant disorder succeeds in key study


Nov 7 Biogen Inc and Ionis Pharmaceuticals said a second late-stage study testing their drug for a rare genetic muscular disorder, the leading genetic cause of death in infants, was successful, prompting them to stop the trial early. Ionis Pharmaceutical's stock jumped up as much as 28.16 percent to $34.77 while Biogen shares rose as much as 7.32 percent to $297.27 in trading on Monday.



from Biotech News